These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 20336784)

  • 1. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
    Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological role and prognostic significance of NAC1 in ovarian cancer.
    Nakayama K; Rahman MT; Rahman M; Yeasmin S; Ishikawa M; Katagiri A; Iida K; Nakayama N; Miyazaki K
    Gynecol Oncol; 2010 Dec; 119(3):469-78. PubMed ID: 20869761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.
    Rahman MT; Nakayama K; Rahman M; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Cancer; 2012 Jun; 118(11):2846-57. PubMed ID: 22139760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
    Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
    Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
    Nakayama K; Rahman MT; Rahman M; Nakamura K; Ishikawa M; Katagiri H; Sato E; Ishibashi T; Iida K; Ishikawa N; Kyo S
    Int J Oncol; 2016 Feb; 48(2):506-16. PubMed ID: 26647729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study.
    Farley J; Smith LM; Darcy KM; Sobel E; O'Connor D; Henderson B; Morrison LE; Birrer MJ;
    Cancer Res; 2003 Mar; 63(6):1235-41. PubMed ID: 12649182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
    Sieuwerts AM; Look MP; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; de Weerd V; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3319-28. PubMed ID: 16740753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
    Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
    Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
    Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
    Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
    Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
    Pils D; Bachmayr-Heyda A; Auer K; Svoboda M; Auner V; Hager G; Obermayr E; Reiner A; Reinthaller A; Speiser P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Berger A; Cacsire Castillo-Tong D; Zeillinger R
    Eur J Cancer; 2014 Jan; 50(1):99-110. PubMed ID: 24176298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
    Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
    Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Kawahara N; Yamada Y; Kobayashi H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.
    Nakamura K; Abarzua F; Kodama J; Hongo A; Nasu Y; Kumon H; Hiramatsu Y
    Int J Oncol; 2009 Feb; 34(2):345-53. PubMed ID: 19148468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
    Davidson B; Skrede M; Silins I; Shih IeM; Trope CG; Flørenes VA
    Cancer; 2007 Sep; 110(6):1264-71. PubMed ID: 17647260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.